Pfizer is closing in on a potential $7.3bn takeover of anti-obesity drug developer Metsera, which would mark the US pharmaceutical company’s first big deal in two years, in a push to give the drugmaker a foothold in the lucrative weight-loss drug market.
辉瑞(Pfizer)正接近以约73亿美元收购抗肥胖药物开发商Metsera，成为这家大型制药集团为在利润丰厚的抗肥胖药物市场站稳脚跟而达成的最大一笔交易。
您已阅读10%（331字），剩余90%（3153字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。